← Back to search
UK HEALTH SECURITY AGENCY
SALISBURY, SP40J
Unclaimed
Prime contracting experience
2 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | UK HEALTH SECURITY AGENCY - BASE (BIO) - IDIQ FOR BARDA BIOLOGICAL ANIMAL MODEL AND MCM DEVELOPMENT | 75A50122D00022USAspending | $5,570,766 | Aug 19, 2026 | Sep 29, 2023 – Sep 28, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | TO ISSUE TASK ORDER B-14 | HHSN272201700027IUSAspending | $1,662,002 | May 28, 2026 | Jul 14, 2017 – May 31, 2026 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Subcontracting experience
10 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | THIS STATEMENT OF WORK (SOW) OUTLINES THE ACTIVITIES THAT UK HEALTH SECURITY AGENCY (UKHSA), PREVIOUSLY KNOWN AS PUBLIC HEALTH ENGLAND (PHE), WILL BE PERFORMING. NOTE THAT THE TASK NUMBERS BELOW REFLECT THE NUMBERING OF THE OVERALL ACTIVITIES IN THE PRIME CONTRACT.
THROUGH THE EXECUTION OF THIS CONTRACT, WE WILL EXAMINE BASIC INDUCTION OF INNATE AND ADAPTIVE IMMUNITY FROM VACCINATION, INCLUDING STUDIES THAT ADDRESS NONTUBERCULOUS MYCOBACTERIA (NTM) INTERFERENCE, RNA DELIVERY, PRIME-BOOST REGIMENS (INCLUDING BCG PRE-EXPOSURE), TRANSCRIPTOMIC HOST SIGNATURES, SYSTEMS BIOLOGY AND DURABLE IMMUNE MEMORY FOR THE FURTHER ADVANCEMENT OF THE EFFORT TO DESIGN AND EVALUATE AN EFFICACIOUS VACCINE AGAINST MYCOBACTERIUM TUBERCULOSIS (M.TB).
THE WORK UNDER THIS CONTRACT MAY INCLUDE THE POSSIBLE DISTRIBUTION OF DE-IDENTIFIED HUMAN SUBJECT PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC), SERUM, AND OTHER CLINICAL SAMPLES TO SCRI AND THE PHOENIX PARTNERS. NHP-DERIVED SAMPLES AND/OR DOWNSTREAM DATA MAY BE SHARED WITH THE PARTNERS ON THIS CONTRACT.
OPTION 2 ACTIVITIES: OBJECTIVE: EVALUATE OPTIMIZED M.TB VACCINE CANDIDATES FOR SAFETY, IMMUNOGENICITY AND EFFICACY IN GUINEA PIG MODEL OF TB
TASK 2.1 EVALUATE IMMUNE RESPONSE OF TB CANDIDATE VACCINES IN GUINEA PIGS
GUINEA PIG IMMUNOLOGY
THE ABILITY TO STUDY IMMUNE RESPONSES IN GUINEA PIGS IS SLOWLY IMPROVING. METHODOLOGY FOR DETERMINING A VARIETY OF CELL- SURFACE MARKERS, CYTOKINES AND CHEMOKINES HAS BEEN DEVELOPED AND STUDIES HAVE BEEN PERFORMED ON BCG-VACCINATED AND M.TB-INFECTED GUINEA PIGS. RELATED SOPS DEVELOPED AT PARTNER INSTITUTES LIKE CSU WILL BE SHARED WITH UKHSA FOR PERFORMANCE OF GUINEA PIG ENDPOINTS AND ASSAY HARMONIZATION. THE NUMBER OF ANTIBODY REAGENTS REMAINS RESTRICTIVE BUT SOME KEY FEATURES OF THE IMMUNE RESPONSE HAVE BEEN DESCRIBED. USING FLOW CYTOMETRY, IT IS POSSIBLE TO MONITOR CD4 AND CD8 T CELLS IN THE LUNGS AND STAINING WITH CD62L PLUS GATING VERSUS CD45 CAN IDENTIFY ACTIVATED T CELLS. FURTHER DEVELOPMENT OF ANTIBODIES TO DETECT IFN-Γ WILL ENABLE INTRACELLULAR STAINING PROTOCOLS TO BE ESTABLISHED. FLOW CYTOMETRY STUDIES HAVE SHOWN THAT CELL ACCUMULATION PATTERNS CHANGE IN BCG VACCINATED GUINEA PIGS AFTER AEROSOL CHALLENGE AND THAT THESE PATTERNS DIFFER FROM THOSE OF THE UNVACCINATED CONTROLS; FOR EXAMPLE, ACTIVATED CD4+ RESPONSES HAVE BEEN SHOWN TO APPEAR MORE RAPIDLY AND THERE WAS A FASTER AND LARGER MACROPHAGE RESPONSE POST-INFECTION IN BCG VACCINATED ANIMALS THAN IN UNVACCINATED CONTROLS. SUCH FINDINGS OFFER THE POTENTIAL FOR IDENTIFICATION OF IMMUNE CORRELATES OF PROTECTION BOTH PRE- AND POST- CHALLENGE. THERE IS NOW A LARGE PANEL OF CYTOKINES (IL-1, IL-4, IL-10, IL-12P40, IFN-Γ, AND TNFΑ) AND CHEMOKINES (IL- 8, MCP-1, TGFΒ, AND RANTES) THAT CAN BE MEASURED BY PCR. THERE ARE A SMALL NUMBER OF ANTIBODY REAGENTS SPECIFIC FOR SOME OF THESE CYTOKINES BEING DEVELOPED BY OUR GROUP AND OTHERS WHICH WILL INCREASE THE SOPHISTICATION OF THESE STUDIES. WORK BY OTHER GROUPS USED MOUSE ANTIBODIES IN A MULTIPLEX ASSAY TO DETECT GUINEA PIG CYTOKINES AND WE PROPOSE TO EVALUATE THIS SYSTEM ON SERA AND ANTIGEN-STIMULATED CELL SUPERNATANTS.
CYTOKINES AND CHEMOKINES: WE HAVE RECENTLY DEVELOPED AN IFN-Γ ELISPOT. INITIATIVES TO FURTHER OPTIMIZE THIS ASSAY ARE ON- GOING. IF SUCH ASSAYS BECOME AVAILABLE, THEY WILL BE USED TO DETECT IFNΓ SECRETION BY CELLS IN WHOLE BLOOD, PMBC OR SPLENOCYTES STIMULATED WITH APPROPRIATE ANTIGENS. OTHER CYTOKINES CAN BE DETECTED USING MOUSE-SPECIFIC ANTIBODIES WHICH CROSS-REACT WITH GUINEA PIG PROTEINS (IL-8 AND TGFΒ), AND GUINEA PIG-SPECIFIC ANTI TNF IS ALSO AVAILABLE. A MULTIPLEX CYTOKINE ASSAY FOR MICE HAS ALSO BEEN SHOWN TO CROSS-REACT WITH GUINEA PIG PROTEINS AND WE WILL INVESTIGATE THESE REAGENTS FOR USE IN A LUMINEX ASSAY FOR GUINEA PIGS. A TNFΑ BIOASSAY HAS ALSO BEEN DESCRIBED TO DETECT ACTIVE TNFΑ, AND THIS ASSAY IS ESTABLISHED AT UKHSA.
LUNG AND SPLEEN TISSUE WILL BE COLLECTED FOR HISTOPATHOLOGICAL EXAMINATION AT POST-MORTEM. THE SAMPLES FOR HISTOLOGY WI SUB00002506 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: WA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $551,442 | Oct 8, 2025 | — – — |
| Subcontractor | Department of Health and Human Services | THIS STATEMENT OF WORK (SOW) OUTLINES THE ACTIVITIES THAT UK HEALTH SECURITY AGENCY (UKHSA), PREVIOUSLY KNOWN AS PUBLIC HEALTH ENGLAND (PHE), WILL BE PERFORMING. NOTE THAT THE TASK NUMBERS BELOW REFLECT THE NUMBERING OF THE OVERALL ACTIVITIES IN THE PRIME CONTRACT.
THROUGH THE EXECUTION OF THIS CONTRACT, WE WILL EXAMINE BASIC INDUCTION OF INNATE AND ADAPTIVE IMMUNITY FROM VACCINATION, INCLUDING STUDIES THAT ADDRESS NONTUBERCULOUS MYCOBACTERIA (NTM) INTERFERENCE, RNA DELIVERY, PRIME-BOOST REGIMENS (INCLUDING BCG PRE-EXPOSURE), TRANSCRIPTOMIC HOST SIGNATURES, SYSTEMS BIOLOGY AND DURABLE IMMUNE MEMORY FOR THE FURTHER ADVANCEMENT OF THE EFFORT TO DESIGN AND EVALUATE AN EFFICACIOUS VACCINE AGAINST MYCOBACTERIUM TUBERCULOSIS (M.TB).
THE WORK UNDER THIS CONTRACT MAY INCLUDE THE POSSIBLE DISTRIBUTION OF DE-IDENTIFIED HUMAN SUBJECT PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC), SERUM, AND OTHER CLINICAL SAMPLES TO SCRI AND THE PHOENIX PARTNERS. NHP-DERIVED SAMPLES AND/OR DOWNSTREAM DATA MAY BE SHARED WITH THE PARTNERS ON THIS CONTRACT.
OPTION 2 ACTIVITIES: OBJECTIVE: EVALUATE OPTIMIZED M.TB VACCINE CANDIDATES FOR SAFETY, IMMUNOGENICITY AND EFFICACY IN GUINEA PIG MODEL OF TB
TASK 2.1 EVALUATE IMMUNE RESPONSE OF TB CANDIDATE VACCINES IN GUINEA PIGS
GUINEA PIG IMMUNOLOGY
THE ABILITY TO STUDY IMMUNE RESPONSES IN GUINEA PIGS IS SLOWLY IMPROVING. METHODOLOGY FOR DETERMINING A VARIETY OF CELL- SURFACE MARKERS, CYTOKINES AND CHEMOKINES HAS BEEN DEVELOPED AND STUDIES HAVE BEEN PERFORMED ON BCG-VACCINATED AND M.TB-INFECTED GUINEA PIGS. RELATED SOPS DEVELOPED AT PARTNER INSTITUTES LIKE CSU WILL BE SHARED WITH UKHSA FOR PERFORMANCE OF GUINEA PIG ENDPOINTS AND ASSAY HARMONIZATION. THE NUMBER OF ANTIBODY REAGENTS REMAINS RESTRICTIVE BUT SOME KEY FEATURES OF THE IMMUNE RESPONSE HAVE BEEN DESCRIBED. USING FLOW CYTOMETRY, IT IS POSSIBLE TO MONITOR CD4 AND CD8 T CELLS IN THE LUNGS AND STAINING WITH CD62L PLUS GATING VERSUS CD45 CAN IDENTIFY ACTIVATED T CELLS. FURTHER DEVELOPMENT OF ANTIBODIES TO DETECT IFN-Γ WILL ENABLE INTRACELLULAR STAINING PROTOCOLS TO BE ESTABLISHED. FLOW CYTOMETRY STUDIES HAVE SHOWN THAT CELL ACCUMULATION PATTERNS CHANGE IN BCG VACCINATED GUINEA PIGS AFTER AEROSOL CHALLENGE AND THAT THESE PATTERNS DIFFER FROM THOSE OF THE UNVACCINATED CONTROLS; FOR EXAMPLE, ACTIVATED CD4+ RESPONSES HAVE BEEN SHOWN TO APPEAR MORE RAPIDLY AND THERE WAS A FASTER AND LARGER MACROPHAGE RESPONSE POST-INFECTION IN BCG VACCINATED ANIMALS THAN IN UNVACCINATED CONTROLS. SUCH FINDINGS OFFER THE POTENTIAL FOR IDENTIFICATION OF IMMUNE CORRELATES OF PROTECTION BOTH PRE- AND POST- CHALLENGE. THERE IS NOW A LARGE PANEL OF CYTOKINES (IL-1, IL-4, IL-10, IL-12P40, IFN-Γ, AND TNFΑ) AND CHEMOKINES (IL- 8, MCP-1, TGFΒ, AND RANTES) THAT CAN BE MEASURED BY PCR. THERE ARE A SMALL NUMBER OF ANTIBODY REAGENTS SPECIFIC FOR SOME OF THESE CYTOKINES BEING DEVELOPED BY OUR GROUP AND OTHERS WHICH WILL INCREASE THE SOPHISTICATION OF THESE STUDIES. WORK BY OTHER GROUPS USED MOUSE ANTIBODIES IN A MULTIPLEX ASSAY TO DETECT GUINEA PIG CYTOKINES AND WE PROPOSE TO EVALUATE THIS SYSTEM ON SERA AND ANTIGEN-STIMULATED CELL SUPERNATANTS.
CYTOKINES AND CHEMOKINES: WE HAVE RECENTLY DEVELOPED AN IFN-Γ ELISPOT. INITIATIVES TO FURTHER OPTIMIZE THIS ASSAY ARE ON- GOING. IF SUCH ASSAYS BECOME AVAILABLE, THEY WILL BE USED TO DETECT IFNΓ SECRETION BY CELLS IN WHOLE BLOOD, PMBC OR SPLENOCYTES STIMULATED WITH APPROPRIATE ANTIGENS. OTHER CYTOKINES CAN BE DETECTED USING MOUSE-SPECIFIC ANTIBODIES WHICH CROSS-REACT WITH GUINEA PIG PROTEINS (IL-8 AND TGFΒ), AND GUINEA PIG-SPECIFIC ANTI TNF IS ALSO AVAILABLE. A MULTIPLEX CYTOKINE ASSAY FOR MICE HAS ALSO BEEN SHOWN TO CROSS-REACT WITH GUINEA PIG PROTEINS AND WE WILL INVESTIGATE THESE REAGENTS FOR USE IN A LUMINEX ASSAY FOR GUINEA PIGS. A TNFΑ BIOASSAY HAS ALSO BEEN DESCRIBED TO DETECT ACTIVE TNFΑ, AND THIS ASSAY IS ESTABLISHED AT UKHSA.
LUNG AND SPLEEN TISSUE WILL BE COLLECTED FOR HISTOPATHOLOGICAL EXAMINATION AT POST-MORTEM. THE SAMPLES FOR HISTOLOGY WI SUB00002380 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: WA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $652,235 | Apr 1, 2025 | — – — |
| Subcontractor | Department of Health and Human Services | THIS STATEMENT OF WORK (SOW) OUTLINES THE ACTIVITIES THAT UK HEALTH SECURITY AGENCY (UKHSA), PREVIOUSLY KNOWN AS PUBLIC HEALTH ENGLAND (PHE), WILL BE PERFORMING. NOTE THAT THE TASK NUMBERS BELOW REFLECT THE NUMBERING OF THE OVERALL ACTIVITIES IN THE PRIME CONTRACT.
THROUGH THE EXECUTION OF THIS CONTRACT, WE WILL EXAMINE BASIC INDUCTION OF INNATE AND ADAPTIVE IMMUNITY FROM VACCINATION, INCLUDING STUDIES THAT ADDRESS NONTUBERCULOUS MYCOBACTERIA (NTM) INTERFERENCE, RNA DELIVERY, PRIME-BOOST REGIMENS (INCLUDING BCG PRE-EXPOSURE), TRANSCRIPTOMIC HOST SIGNATURES, SYSTEMS BIOLOGY AND DURABLE IMMUNE MEMORY FOR THE FURTHER ADVANCEMENT OF THE EFFORT TO DESIGN AND EVALUATE AN EFFICACIOUS VACCINE AGAINST MYCOBACTERIUM TUBERCULOSIS (M.TB).
THE WORK UNDER THIS CONTRACT MAY INCLUDE THE POSSIBLE DISTRIBUTION OF DE-IDENTIFIED HUMAN SUBJECT PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC), SERUM, AND OTHER CLINICAL SAMPLES TO SCRI AND THE PHOENIX PARTNERS. NHP SAMPLES AND/OR DOWNSTREAM DATA MAY BE SHARED WITH THE PARTNERS ON THIS CONTRACT.
OPTION 3.M72 ACTIVITIES:
THE ANIMALS USED IN THESE STUDIES WILL BE RHESUS MACAQUES OF INDIAN GENOTYPE OBTAINED FROM ESTABLISHED UK BREEDING COLONIES AND WILL BE BETWEEN 3 AND 6 YEARS OF AGE (TYPICALLY BETWEEN 4 – 12 KG). ABSENCE OF PREVIOUS EXPOSURE TO MYCOBACTERIAL ANTIGENS AND/OR NTM RECOGNITION WILL BE CONFIRMED BY EX VIVO IFN-Γ ELISPOT TO MEASURE RESPONSES TO PURIFIED PROTEIN DERIVATIVE (PPD) FROM M.TB, POOLED 15-MER PEPTIDES OF ESAT-6 AND CFP-10 AND NTM MEGA PEPTIDE POOLS FOR SCREENING TIMEPOINTS AND MTB300 FOR POST VACCINATION AND M.TB CHALLENGE TIMEPOINTS AS AVAILABLE. THE PROJECT LICENSE ENABLING THESE STUDIES WILL BE APPROVED BY THE ANIMAL WELFARE AND ETHICAL REVIEW BODY AT UKHSA PORTON AND GRANTED BY THE HOME OFFICE, UK. ANIMALS WILL BE HOUSED IN SOCIALLY COMPATIBLE GROUPS AND ACCORDING TO THE CODE OF PRACTICE FOR THE HOUSING AND CARE OF ANIMALS BRED, SUPPLIED OR USED FOR SCIENTIFIC PURPOSES, DECEMBER 2014, THE NC3RS, AND THE GUIDELINES ON PRIMATE ACCOMMODATION, CARE AND USE, AUGUST 2006 (NC3RS, 2006).
ANIMALS WILL BE MONITORED DAILY FOR BEHAVIORAL AND CLINICAL CHANGES. BEHAVIOR WILL BE EVALUATED FOR CONTRA-INDICATORS INCLUDING DEPRESSION, WITHDRAWAL FROM THE GROUP, AGGRESSION, CHANGES IN FEEDING PATTERNS, BREATHING PATTERN, RESPIRATION RATE AND COUGH. BLOOD SAMPLE COLLECTION (PAXGENE) FOR TRANSCRIPTOMICS WILL BE COLLECTED TWO DAYS AFTER EACH IMMUNIZATION OR CHALLENGE. BLOOD SAMPLE COLLECTION FOR M.TB ANTIGEN-SPECIFIC IMMUNE RESPONSES WILL BE EVALUATED AT REGULAR INTERVALS THROUGHOUT THE STUDY (HIGH PRIORITY TIMEPOINTS TO INCLUDE: TWO WEEKS POST PRIME AND BOOST IMMUNIZATIONS, ONE WEEK PRE-CHALLENGE, ONE, TWO, FOUR AND EIGHT WEEKS POST CHALLENGE), AEROSOL CHALLENGE AND EUTHANASIA; ANIMALS WILL BE WEIGHED, EXAMINED FOR GROSS ABNORMALITIES AND BODY TEMPERATURE MEASURED. RED BLOOD CELL (RBC) HEMOGLOBIN LEVELS WILL BE MEASURED TO IDENTIFY THE PRESENCE OF ANEMIA, AND ERYTHROCYTE SEDIMENTATION RATES (ESR) WILL BE MEASURED TO DETECT AND MONITOR INFLAMMATION INDUCED BY INFECTION WITH M.TB.
TASK 3.M72: USE ULDA MODEL TO EVALUATE THE EFFICACY OF NEW TB VACCINE CANDIDATES
NOTE: AFTER REVIEW OF ALL UPCOMING EXPERIMENTS, THE NIH, SCRI AND UKHSA AGREED THAT THE FOLLOWING EXPERIMENT COMBINING BOTH ID93 AND M72 VACCINE GROUPS IS PREFERRED GIVEN IT IS BOTH COST SAVING (SHARED CONTROLS) AND SCIENTIFICALLY MORE ROBUST (DIRECT HEAD TO HEAD) THAN THE EXPERIMENTAL DESIGNS AS SEPARATE TASKS. THEREFORE, THIS WORK IS DESCRIBED IN OPTION 3 SOW AS WELL AS OPTION M72.3 SOW. GROUPS BOLDED BELOW WILL BE SPECIFICALLY PAID FOR WITH 3.M72 FUNDING, WITH CONTROLS AS A SHARED COST WITH OPTION 3.3.
TABLE 1: PRECLINICAL DESIGN FOR TASK M72.3
GROUP PRIME FIRST BOOST SECOND BOOST1 CHALLENGE2
1 SALINE SALINE SALINE CLINICAL M.TB ISOLATE HN878 - ULDA
2 BCG SALINE SALINE
3 BCG M72+GLA-LSQ M72+GLA-LSQ
4 BCG ID93+GLA-LSQ ID93+GLA-LSQ
5 BCG M72+GLA-SE M72+GLA-SE
6 BCG M72+UM-1098 M72+UM-1098
1 SECOND BOOST DELIVERED I.M. 56 DAYS POST FIR SUB00002381 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: WA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $1,833,576 | Apr 1, 2025 | — – — |
| Subcontractor | Department of Health and Human Services | THROUGH THE EXECUTION OF THIS CONTRACT, WE WILL EXAMINE BASIC INDUCTION OF INNATE AND ADAPTIVE IMMUNITY FROM VACCINATION, INCLUDING STUDIES THAT ADDRESS NONTUBERCULOUS MYCOBACTERIA (NTM) INTERFERENCE, RNA DELIVERY, PRIME-BOOST REGIMENS (INCLUDING BCG PRE-EXPOSURE), TRANSCRIPTOMIC HOST SIGNATURES, SYSTEMS BIOLOGY AND DURABLE IMMUNE MEMORY FOR THE FURTHER ADVANCEMENT OF THE EFFORT TO DESIGN AND EVALUATE AN EFFICACIOUS VACCINE AGAINST MYCOBACTERIUM TUBERCULOSIS (M.TB).
THE WORK UNDER THIS CONTRACT MAY INCLUDE THE POSSIBLE DISTRIBUTION OF DE-IDENTIFIED HUMAN SUBJECT PBMC SAMPLES TO SCRI AND THE PHOENIX PARTNERS. 13377SUB Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: WA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $199,093 | Jul 29, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | THROUGH THE EXECUTION OF THIS CONTRACT, WE WILL EXAMINE BASIC INDUCTION OF INNATE AND ADAPTIVE IMMUNITY
FROM VACCINATION, INCLUDING STUDIES THAT ADDRESS NONTUBERCULOUS MYCOBACTERIA (NTM) INTERFERENCE, RNA
DELIVERY, PRIME-BOOST REGIMENS (INCLUDING BCG PRE-EXPOSURE), TRANSCRIPTOMIC HOST SIGNATURES, SYSTEMS
BIOLOGY AND DURABLE IMMUNE MEMORY FOR THE FURTHER ADVANCEMENT OF THE EFFORT TO DESIGN AND EVALUATE AN
EFFICACIOUS VACCINE AGAINST MYCOBACTERIUM TUBERCULOSIS (M.TB). 13375SUB Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: WA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $1,427,801 | Jul 25, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | NON-HUMAN PRIMATE LUNG CHIPS FOR TESTING COVID19 THERAPIES
TASK 1. NON-HUMAN PRIMATE CELL ISOLATION
THE CELL ISOLATIONS WILL BE CARRIED OUT IN ONE ANIMAL APPROXIMATELY EVERY 4 MONTHS, UP TO A TOTAL OF 3 ANIMALS. LUNG MICROVASCULAR ENDOTHELIAL CELLS AND PERIPHERAL BLOOD MONONUCLEAR (PBMC) CELLS WILL BE ISOLATED, CRYOPRESERVED AND PROVIDED TO THE WYSS TEAM.
TASK 2. CITES PERMITS
MATERIAL DERIVED FROM NON-HUMAN PRIMATES MUST BE SHIPPED UNDER CONVENTION ON INTERNATIONAL TRADE IN ENDANGERED SPECIES(CITES) EXPORT AND IMPORT PERMITS. UKHSA WILL OBTAIN THE REQUIRED EXPORT PERMITS.
TASK 3. TO TRANSFER TECHNICAL KNOW-HOW IN CREATING NHP LUNG CHIPS TO UKHSA
THE WYSS INSTITUTE WILL TRANSFER DETAILED PROTOCOLS FOR THE LUNG NHP CHIPS TO THE TEAM AT UKHSA. 168024-5121883 Parent award context Parent award agency: Department of Health and Human Services · Food and Drug Administration Parent award NAICS: 541690 Parent award performance state: MA Parent award description: BAA MCMWP #71 "HUMAN ORGAN CHIPS FOR RADIATION COUNTERMEASURE DEVELOPMENT" View parent award on USAspending | — | $0 | Jun 28, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | THROUGH THE EXECUTION OF THIS CONTRACT, WE WILL EXAMINE BASIC INDUCTION OF INNATE AND ADAPTIVE IMMUNITY FROM VACCINATION, INCLUDING STUDIES THAT ADDRESS NTM INTERFERENCE, RNA DELIVERY, PRIME-BOOST REGIMENS (INCLUDING BCG PRE-EXPOSURE), TRANSCRIPTOMIC HOST SIGNATURES, PROTEOMICS, SYSTEMS BIOLOGY AND DURABLE IMMUNE MEMORY FOR THE FURTHER ADVANCEMENT OF THE EFFORT TO DESIGN AND EVALUATE AN EFFICACIOUS VACCINE AGAINST MYCOBACTERIUM TUBERCULOSIS (M.TB).
BASE ACTIVITIES: DEVELOP IMMUNE RESPONSE ASSAYS AND HARMONIZE PROTOCOLS AND ASSAYS
TASK B.2: IMMUNOLOGICAL ASSAY DEVELOPMENT, HARMONIZATION OF PROTOCOLS AND IN VIVO STUDIES
TO ENSURE THAT BIOLOGICAL RESULTS GENERATED IN THE VARIOUS CONSORTIUM LABS ARE COMPARABLE, WE WILL STANDARDIZE THE PRIMARY ASSAYS USED IN IMMUNOGENICITY ASSESSMENTS FOR EACH SPECIES (TABLE 1). IN LINE WITH THE PROJECT GOALS TO DEVELOP A CROSS-SPECIES INTERROGATION PLATFORM, WE WILL HARMONIZE KEY ASSAYS ACROSS MULTIPLE SPECIES INCLUDING GUINEA PIG AND NHP MODELS PERFORMED AT UKHSA. SCRI WILL APPOINT AN OVERALL TASK LEADER TO COORDINATE AND OVERSEE THE WORK. ALL ASSAY STANDARD OPERATING PROCEDURES (SOP) WILL BE SHARED WITH A PRECLINICAL LABORATORY LEAD, DESIGNATED FOR EACH ASSAY, WHO WILL BE RESPONSIBLE FOR HARMONIZING. FINAL SOPS WILL BE SHARED AND LEAD ASSAY LABS WILL CONDUCT SIDE-BY-SIDE TRAINING SESSIONS, AS WELL AS, MAINTAIN AND DISTRIBUTE COMMON REFERENCE STANDARDS AND REAGENTS, SUCH AS IDENTICAL STIMULATION ANTIGENS (BCG, PPD, SEB, 15-MER PEPTIDES, NTM AND M.TB LYSATES OR CULTURE FILTRATES AND UNSTIMULATED) AND BCG VACCINATION STRAIN (BCG AJ/BCG SSI). THIS BASE-PERIOD HARMONIZATION WILL INCLUDE OPTIMIZED MULTICOLOR IMMUNOFLUORESCENCE PANEL (OMIP) (19-COLOR) DEVELOPMENT, USING ARCHIVED NHP PMBC SAMPLES TO CONVERT THE HUMAN PANEL TO NHP REAGENTS AND HIGH PERFORMANCE. FURTHERMORE, IN THE BASE PERIOD WE WILL AGREE TO A SPECIFIC MONTH IN WHICH EACH TEAM WILL ANNUALLY THAW INFECTION STOCKS AND PLATE FOR BACTERIAL ENUMERATION TO ENSURE VIABILITY AND STOCK CONCENTRATION IS MAINTAINED OVER THE ENTIRE COURSE OF THE CONTRACT. THESE STOCK COUNTS AND VIABILITY MAINTENANCE TESTS WILL BE REPORTED BACK TO SCRI.
TABLE 1. ASSAY HARMONIZATION STRATEGY
ASSAY PURPOSE SPECIES SPECIMEN CLINICAL LEAD PRECLINICAL LEAD
ELISA QUANTITATE ANTIGEN-SPECIFIC ANTIBODY TITERS HUMAN, NHP, MICE, GUINEA PIG SERUM RAGON SCRI
ICS QUANTITATE FREQUENCIES/PHENOTYPE OF ANTIGEN-SPECIFIC T CELLS, OMIP DEVELOPMENT HUMAN*,�®, NHP�®, MICE�® WHOLE BLOOD* OR PBMC�® OXFORD SCRI
IFN-γ ELISPOT QUANTITATE NUMBERS OF ANTIGEN-SPECIFIC T CELLS HUMAN, NHP PBMC OXFORD ND
CYTOKINE MULTIPLEX QUANTITATE CYTOKINE SECRETION FROM STIMULATED WHOLE BLOOD HUMAN#,*, NHP #, MICE# WHOLE BLOOD* OR SERUM# SCRI ND
MGIA MEASURE MYCOBACTERIAL GROWTH INHIBITION HUMAN �®, NHP*, MICE^ PBMC �®, SPLENOCYTES^, WHOLE BLOOD* OXFORD OXFORD
CFU BACTERIAL BURDEN HUMAN™¦, NHP, MICE™¦, GUINEA PIG™¦ ORGAN TISSUE, BAL™¦ OXFORD SCRI
QPCR BIOMARKER FLUIDIGM/ NANOSTRING GENE EXPRESSION PROFILE HUMAN*, NHP*, MICE*,~, GUINEA PIG WHOLE BLOOD*, BAL, LUNG~ FHCRC FHCRC
PROTEOMICS PROTEIN EXPRESSION PROFILE HUMAN, NHP, MICE, GUINEA PIG SERUM CSU CSU
SYSTEMS SEROLOGY FUNCTIONAL ANTIBODY PROFILING HUMAN, NHP, MICE, GUINEA PIG SERUM RAGON RAGON
EX VIVO MACROPHAGE ASSAY FUNCTIONAL ASSESSMENT OF MACROPHAGE KILLING HUMAN, NHP, MICE, GUINEA PIG ALVEOLAR MACROPHAGES, MDM DRI DRI
ND €€Œ NOT DONE, NO NEED OR LESS FEASIBLE FOR WITHIN SPECIES HARMONIZATION
ROUTINE COLLECTION OF PRECLINICAL GUINEA PIG AND NHP SAMPLES AND PERFORMING ASSAYS (OR SURROGATE ASSAYS) TYPICALLY USED TO ASSESS VACCINE RESPONSES IN HUMANS ALONG WITH PRECLINICAL VACCINE EFFICACY ASSAYS WILL BE EXECUTED IN ORDER TO ADVANCE SOP AND ASSAY HARMONIZATION. SOME OF THE HARVESTED SAMPLES (EX. SERUM AND BLOOD) OR SAMPLES STORED FROM PREVIOUS WORK ALLOCATED TO THIS TASK WILL BE DISTRIBUTED TO COLLABORATOR SITES AS SPECIMENS TO USE AS PART OF THE ASSAY HARMONIZATION AND SIDE-BY-SIDE EVALUATION OF DATA FROM DIFFER 12963SUB Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: WA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $1,193,667 | Apr 30, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | THROUGH THE EXECUTION OF THIS CONTRACT, WE WILL EXAMINE BASIC INDUCTION OF INNATE AND ADAPTIVE IMMUNITY FROM VACCINATION, INCLUDING STUDIES THAT ADDRESS NTM INTERFERENCE, RNA DELIVERY, PRIME-BOOST REGIMENS (INCLUDING BCG PRE-EXPOSURE), TRANSCRIPTOMIC HOST SIGNATURES, PROTEOMICS, SYSTEMS BIOLOGY AND DURABLE IMMUNE MEMORY FOR THE FURTHER ADVANCEMENT OF THE EFFORT TO DESIGN AND EVALUATE AN EFFICACIOUS VACCINE AGAINST MYCOBACTERIUM TUBERCULOSIS (M.TB).
BASE ACTIVITIES: DEVELOP IMMUNE RESPONSE ASSAYS AND HARMONIZE PROTOCOLS AND ASSAYS
TASK B.2: IMMUNOLOGICAL ASSAY DEVELOPMENT, HARMONIZATION OF PROTOCOLS AND IN VIVO STUDIES
TO ENSURE THAT BIOLOGICAL RESULTS GENERATED IN THE VARIOUS CONSORTIUM LABS ARE COMPARABLE, WE WILL STANDARDIZE THE PRIMARY ASSAYS USED IN IMMUNOGENICITY ASSESSMENTS FOR EACH SPECIES (TABLE 1). IN LINE WITH THE PROJECT GOALS TO DEVELOP A CROSS-SPECIES INTERROGATION PLATFORM, WE WILL HARMONIZE KEY ASSAYS ACROSS MULTIPLE SPECIES INCLUDING GUINEA PIG AND NHP MODELS PERFORMED AT UKHSA. SCRI WILL APPOINT AN OVERALL TASK LEADER TO COORDINATE AND OVERSEE THE WORK. ALL ASSAY STANDARD OPERATING PROCEDURES (SOP) WILL BE SHARED WITH A PRECLINICAL LABORATORY LEAD, DESIGNATED FOR EACH ASSAY, WHO WILL BE RESPONSIBLE FOR HARMONIZING. FINAL SOPS WILL BE SHARED AND LEAD ASSAY LABS WILL CONDUCT SIDE-BY-SIDE TRAINING SESSIONS, AS WELL AS, MAINTAIN AND DISTRIBUTE COMMON REFERENCE STANDARDS AND REAGENTS, SUCH AS IDENTICAL STIMULATION ANTIGENS (BCG, PPD, SEB, 15-MER PEPTIDES, NTM AND M.TB LYSATES OR CULTURE FILTRATES AND UNSTIMULATED) AND BCG VACCINATION STRAIN (BCG AJ/BCG SSI). THIS BASE-PERIOD HARMONIZATION WILL INCLUDE OPTIMIZED MULTICOLOR IMMUNOFLUORESCENCE PANEL (OMIP) (19-COLOR) DEVELOPMENT, USING ARCHIVED NHP PMBC SAMPLES TO CONVERT THE HUMAN PANEL TO NHP REAGENTS AND HIGH PERFORMANCE. FURTHERMORE, IN THE BASE PERIOD WE WILL AGREE TO A SPECIFIC MONTH IN WHICH EACH TEAM WILL ANNUALLY THAW INFECTION STOCKS AND PLATE FOR BACTERIAL ENUMERATION TO ENSURE VIABILITY AND STOCK CONCENTRATION IS MAINTAINED OVER THE ENTIRE COURSE OF THE CONTRACT. THESE STOCK COUNTS AND VIABILITY MAINTENANCE TESTS WILL BE REPORTED BACK TO SCRI.
TABLE 1. ASSAY HARMONIZATION STRATEGY
ASSAY PURPOSE SPECIES SPECIMEN CLINICAL LEAD PRECLINICAL LEAD
ELISA QUANTITATE ANTIGEN-SPECIFIC ANTIBODY TITERS HUMAN, NHP, MICE, GUINEA PIG SERUM RAGON SCRI
ICS QUANTITATE FREQUENCIES/PHENOTYPE OF ANTIGEN-SPECIFIC T CELLS, OMIP DEVELOPMENT HUMAN*,�®, NHP�®, MICE�® WHOLE BLOOD* OR PBMC�® OXFORD SCRI
IFN-γ ELISPOT QUANTITATE NUMBERS OF ANTIGEN-SPECIFIC T CELLS HUMAN, NHP PBMC OXFORD ND
CYTOKINE MULTIPLEX QUANTITATE CYTOKINE SECRETION FROM STIMULATED WHOLE BLOOD HUMAN#,*, NHP #, MICE# WHOLE BLOOD* OR SERUM# SCRI ND
MGIA MEASURE MYCOBACTERIAL GROWTH INHIBITION HUMAN �®, NHP*, MICE^ PBMC �®, SPLENOCYTES^, WHOLE BLOOD* OXFORD OXFORD
CFU BACTERIAL BURDEN HUMAN™¦, NHP, MICE™¦, GUINEA PIG™¦ ORGAN TISSUE, BAL™¦ OXFORD SCRI
QPCR BIOMARKER FLUIDIGM/ NANOSTRING GENE EXPRESSION PROFILE HUMAN*, NHP*, MICE*,~, GUINEA PIG WHOLE BLOOD*, BAL, LUNG~ FHCRC FHCRC
PROTEOMICS PROTEIN EXPRESSION PROFILE HUMAN, NHP, MICE, GUINEA PIG SERUM CSU CSU
SYSTEMS SEROLOGY FUNCTIONAL ANTIBODY PROFILING HUMAN, NHP, MICE, GUINEA PIG SERUM RAGON RAGON
EX VIVO MACROPHAGE ASSAY FUNCTIONAL ASSESSMENT OF MACROPHAGE KILLING HUMAN, NHP, MICE, GUINEA PIG ALVEOLAR MACROPHAGES, MDM DRI DRI
ND €€Œ NOT DONE, NO NEED OR LESS FEASIBLE FOR WITHIN SPECIES HARMONIZATION
ROUTINE COLLECTION OF PRECLINICAL GUINEA PIG AND NHP SAMPLES AND PERFORMING ASSAYS (OR SURROGATE ASSAYS) TYPICALLY USED TO ASSESS VACCINE RESPONSES IN HUMANS ALONG WITH PRECLINICAL VACCINE EFFICACY ASSAYS WILL BE EXECUTED IN ORDER TO ADVANCE SOP AND ASSAY HARMONIZATION. SOME OF THE HARVESTED SAMPLES (EX. SERUM AND BLOOD) OR SAMPLES STORED FROM PREVIOUS WORK ALLOCATED TO THIS TASK WILL BE DISTRIBUTED TO COLLABORATOR SITES AS SPECIMENS TO USE AS PART OF THE ASSAY HARMONIZATION AND SIDE-BY-SIDE EVALUATION OF DATA FROM DIFFER 12962SUB Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: WA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $154,839 | Apr 30, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | NON-HUMAN PRIMATE LUNG CHIPS FOR
TESTING COVID19 THERAPIES
TASK 1. NON-HUMAN PRIMATE CELL ISOLATION
THE CELL ISOLATIONS WILL BE CARRIED OUT IN ONE ANIMAL APPROXIMATELY EVERY 4 MONTHS, UP TO A TOTAL OF 3 ANIMALS. LUNG MICROVASCULAR ENDOTHELIAL CELLS AND PERIPHERAL BLOOD MONONUCLEAR (PBMC)
CELLS WILL BE ISOLATED, CRYOPRESERVED AND PROVIDED TO THE WYSS TEAM.
TASK 2. CITES PERMITS
MATERIAL DERIVED FROM NON-HUMAN PRIMATES MUST BE SHIPPED UNDER CONVENTION ON INTERNATIONAL TRADE IN ENDANGERED SPECIES(CITES) EXPORT AND IMPORT PERMITS. UKHSA WILL OBTAIN THE REQUIRED EXPORT PERMITS.
TASK 3. TO TRANSFER TECHNICAL KNOW-HOW IN CREATING NHP LUNG CHIPS TO UKHSA
THE WYSS INSTITUTE WILL TRANSFER DETAILED PROTOCOLS FOR THE LUNG NHP CHIPS TO THE TEAM AT UKHSA. 168024-5121883 Parent award context Parent award agency: Department of Health and Human Services · Food and Drug Administration Parent award NAICS: 541690 Parent award performance state: MA Parent award description: BAA MCMWP #71 "HUMAN ORGAN CHIPS FOR RADIATION COUNTERMEASURE DEVELOPMENT" View parent award on USAspending | — | $146,070 | Oct 21, 2022 | — – — |
| Subcontractor | Department of Health and Human Services | THROUGH THE EXECUTION OF THIS CONTRACT, WE WILL EXAMINE BASIC INDUCTION OF INNATE AND ADAPTIVE IMMUNITY FROM VACCINATION, INCLUDING STUDIES THAT ADDRESS NTM INTERFERENCE, RNA DELIVERY, PRIME-BOOST REGIMENS (INCLUDING BCG PRE-EXPOSURE), TRANSCRIPTOMIC HOST SIGNATURES, PROTEOMICS, SYSTEMS BIOLOGY AND DURABLE IMMUNE MEMORY FOR THE FURTHER ADVANCEMENT OF THE EFFORT TO DESIGN AND EVALUATE AN EFFICACIOUS VACCINE AGAINST MYCOBACTERIUM TUBERCULOSIS (M.TB).
BASE ACTIVITIES: DEVELOP IMMUNE RESPONSE ASSAYS AND HARMONIZE PROTOCOLS AND ASSAYS
TASK B.2: IMMUNOLOGICAL ASSAY DEVELOPMENT, HARMONIZATION OF PROTOCOLS AND IN VIVO STUDIES
TO ENSURE THAT BIOLOGICAL RESULTS GENERATED IN THE VARIOUS CONSORTIUM LABS ARE COMPARABLE, WE WILL STANDARDIZE THE PRIMARY ASSAYS USED IN IMMUNOGENICITY ASSESSMENTS FOR EACH SPECIES (TABLE 1). IN LINE WITH THE PROJECT GOALS TO DEVELOP A CROSS-SPECIES INTERROGATION PLATFORM, WE WILL HARMONIZE KEY ASSAYS ACROSS MULTIPLE SPECIES INCLUDING GUINEA PIG AND NHP MODELS PERFORMED AT UKHSA. SCRI WILL APPOINT AN OVERALL TASK LEADER TO COORDINATE AND OVERSEE THE WORK. ALL ASSAY STANDARD OPERATING PROCEDURES (SOP) WILL BE SHARED WITH A PRECLINICAL LABORATORY LEAD, DESIGNATED FOR EACH ASSAY, WHO WILL BE RESPONSIBLE FOR HARMONIZING. FINAL SOPS WILL BE SHARED AND LEAD ASSAY LABS WILL CONDUCT SIDE-BY-SIDE TRAINING SESSIONS, AS WELL AS, MAINTAIN AND DISTRIBUTE COMMON REFERENCE STANDARDS AND REAGENTS, SUCH AS IDENTICAL STIMULATION ANTIGENS (BCG, PPD, SEB, 15-MER PEPTIDES, NTM AND M.TB LYSATES OR CULTURE FILTRATES AND UNSTIMULATED) AND BCG VACCINATION STRAIN (BCG AJ/BCG SSI). THIS BASE-PERIOD HARMONIZATION WILL INCLUDE OPTIMIZED MULTICOLOR IMMUNOFLUORESCENCE PANEL (OMIP) (19-COLOR) DEVELOPMENT. FURTHERMORE, IN THE BASE PERIOD WE WILL AGREE TO A SPECIFIC MONTH IN WHICH EACH TEAM WILL ANNUALLY THAW INFECTION STOCKS AND PLATE FOR BACTERIAL ENUMERATION TO ENSURE VIABILITY AND STOCK CONCENTRATION IS MAINTAINED OVER THE ENTIRE COURSE OF THE CONTRACT. THESE STOCK COUNTS AND VIABILITY MAINTENANCE TESTS WILL BE REPORTED BACK TO SCRI.
TABLE 1. ASSAY HARMONIZATION STRATEGY
ASSAY PURPOSE SPECIES SPECIMEN CLINICAL LEAD PRECLINICAL LEAD
ELISA QUANTITATE ANTIGEN-SPECIFIC ANTIBODY TITERS HUMAN, NHP, MICE, GUINEA PIG SERUM RAGON SCRI
ICS QUANTITATE FREQUENCIES/PHENOTYPE OF ANTIGEN-SPECIFIC T CELLS, OMIP DEVELOPMENT HUMAN*,�®, NHP�®, MICE�® WHOLE BLOOD* OR PBMC�® OXFORD SCRI
IFN-γ ELISPOT QUANTITATE NUMBERS OF ANTIGEN-SPECIFIC T CELLS HUMAN, NHP PBMC OXFORD ND
CYTOKINE MULTIPLEX QUANTITATE CYTOKINE SECRETION FROM STIMULATED WHOLE BLOOD HUMAN#,*, NHP #, MICE# WHOLE BLOOD* OR SERUM# SCRI ND
MGIA MEASURE MYCOBACTERIAL GROWTH INHIBITION HUMAN �®, NHP*, MICE^ PBMC �®, SPLENOCYTES^, WHOLE BLOOD* OXFORD OXFORD
CFU BACTERIAL BURDEN HUMAN™¦, NHP, MICE™¦, GUINEA PIG™¦ ORGAN TISSUE, BAL™¦ OXFORD SCRI
QPCR BIOMARKER FLUIDIGM/ NANOSTRING GENE EXPRESSION PROFILE HUMAN*, NHP, MICE*,~, GUINEA PIG WHOLE BLOOD*, BAL™¦, LUNG~ FHCRC FHCRC
PROTEOMICS PROTEIN EXPRESSION PROFILE HUMAN, NHP, MICE, GUINEA PIG BLOOD AND SERUM CSU CSU
SYSTEMS SEROLOGY FUNCTIONAL ANTIBODY PROFILING HUMAN, NHP, MICE, GUINEA PIG SERUM RAGON RAGON
EX VIVO MACROPHAGE ASSAY FUNCTIONAL ASSESSMENT OF MACROPHAGE KILLING HUMAN, NHP, MICE, GUINEA PIG ALVEOLAR MACROPHAGES, MDM DRI DRI
ND €€Œ NOT DONE, NO NEED OR LESS FEASIBLE FOR WITHIN SPECIES HARMONIZATION
ROUTINE COLLECTION OF PRECLINICAL GUINEA PIG AND NHP SAMPLES AND PERFORMING ASSAYS (OR SURROGATE ASSAYS) TYPICALLY USED TO ASSESS VACCINE RESPONSES IN HUMANS ALONG WITH PRECLINICAL VACCINE EFFICACY ASSAYS WILL BE EXECUTED IN ORDER TO ADVANCE SOP AND ASSAY HARMONIZATION. SOME OF THE HARVESTED SAMPLES (EX. SERUM AND BLOOD) OR SAMPLES STORED FROM PREVIOUS WORK ALLOCATED TO THIS TASK WILL BE DISTRIBUTED TO COLLABORATOR SITES AS SPECIMENS TO USE AS PART OF THE ASSAY HARMONIZATION AND SIDE-BY-SIDE EVALUATION OF DATA FROM DIFFERENT LOCATIONS. UKHSA WILL PROVIDE THESE SAMPLES TO COLLABORATORS AS NEEDED AND PR 12809SUB Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: WA Parent award description: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) View parent award on USAspending | — | $267,714 | Sep 30, 2022 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Health and Human ServicesGov-sourced